肥胖治療藥物之新進展：Phentermine/Topiramate複方

Advances in the Treatment of Obesity: The Combination of Phentermine and Topiramate

肥胖是許多慢性病重要危險因子，也是全球重視的健康議題。過去許多藥物曾被用於肥胖治療，但卻因安全性考量先後下市，目前僅少數藥物被核准於肥胖長期治療。2012年7月，美國食品藥物管理局核准phentermine/topiremate複方上市，用於肥胖或體重過重且至少有一項肥胖相關共病症（包含第二型糖尿病、高血壓或高血脂症等）病人，搭配飲食與運動控制的長期藥物治療。本文將簡介該藥的藥理特性與相關臨床試驗結果，以供醫療人員參考。

Obesity is a major risk factor for numerous chronic diseases and a global health-related issue. Many drugs used for weight loss have been withdrawn from the market for safety reasons, and only a few medications are currently approved for the long-term treatment of obesity. In July 2012, U.S. Food and Drug Administration approved the combination of phentermine and topiramate as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (body mass index, BMI of≧30kg/m2) or overweight adults (BMI≧27/kg/m2) having at least one obesity-related comorbidity (e.g., type 2 diabetes mellitus, hypertension, or hyperlipidemia). This article provides health professionals with concise information about the pharmacological action underlying their combined use and the results of clinical trials.